Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7443884 | 0.81 | ANPEP (0.51) | KMT2AANPEP | |
| SCHEMBL5422146 | 0.79 | CTSS (0.52) | ACE | |
| SCHEMBL2164026 | 0.77 | METAP2 (0.50) | KMT2AMETAP2PPARGPPARAACE | |
| SCHEMBL2164032 | 0.77 | METAP2 (0.50) | KMT2AMETAP2PPARGPPARAACE | |
| SCHEMBL4141148 | 0.76 | METAP2 (0.52) | METAP2PPARGPPARAACEL3MBTL1 | |
| SCHEMBL9207368 | 0.76 | METAP2 (0.46) | METAP2PPARGPPARAACEL3MBTL1 | |
| SCHEMBL1839764 | 0.76 | METAP2 (0.52) | METAP2PPARGPPARAACEL3MBTL1 | |
| SCHEMBL10980774 | 0.76 | METAP2 (0.46) | KMT2AMETAP2PPARGPPARAACE | |
| SCHEMBL2553802 | 0.76 | METAP2 (0.52) | METAP2PPARGPPARAACEL3MBTL1 | |
| Cyanide SCHEMBL28390031 | 0.75 | METAP2 (0.49) | METAP2PPARGPPARAACEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| WO-2025226892-A1 | SPIROCYCLE-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4288426-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | Black Diamond Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117203202-A | Quinoxaline derivative and use thereof | 黑钻治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2022170122-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | NQO2, NQO1, GLS | KMT2A 2657/4885METAP2 3682/4885PPARG 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.